5-苄基-3,6-二氧代-2-哌嗪乙酸
2-Piperazineaceticacid, 3,6-dioxo-5-(phenylmethyl)-, (2S,5S)-;(2S-cis)-(−)-5-Benzyl-3,6-dioxo-2-piperazineacetic acid;2-((2S,5S)-5-Benzyl-3,6-dioxopiperazin-2-yl)acetic acid;Aspartame-Related Compound A, (2S,5S)-5-Benzyl-3,6-dioxo2-piperazineacetic acid;Cyclo(-Asp-Phe);(2S,5S)-5-Benzyl-3,6-dioxo-2-piperazineacetic Acid;2-[(2S,5S)-5-benzyl-3,6-dioxopiperazin-2-yl]acetic acid;5-Benzyl-3,6-dioxo-2-piperazineacetic Acid;AspartaMe Related CoMpound A;2-Piperazineacetic acid, 3,6-dioxo-5-(phenylmethyl)-, (2S,5S)-;SCHEMBL3956081;3,6-DIOXO-5-(PHENYLMETHYL)-2-PIPERAZINEACETIC ACID, (2S,5S)-;NCGC00160216-01;Cyclo(aspartyl-phenylalanyl);ASPARTAME DIKETOPIPERAZINE;E80547;UNII-ZM82VP15YJ;MFCD00190764;5262-10-2;ZM82VP15YJ;(2S-cis)-5-Benzyl-3,6-dioxopiperazine-2-acetic acid;(2S-cis)-(-)-5-Benzyl-3,6-dioxo-2-piperazineacetic acid, analytical standard;2-PIPERAZINEACETIC ACID, 3,6-DIOXO-5-(PHENYLMETHYL)-, (2S-CIS)-;(2S,5S)-3,6-Dioxo-5-(phenylmethyl)-2-piperazineacetic Acid;A15034;CHEMBL1213197;NS00044819;Cyclo(Asp-Phe);3-Phenylmethyl-2,5-diketopiperazine-6-acetic acid;Q27295736;(2S-cis)-(-)-5-Benzyl-3,6-dioxo-2-piperazineacetic acid;2-((2S,5S)-5-benzyl-3,6-dioxopiperazin-2-yl)acetic acid;CCRIS 5457;Aspartame impurity A, European Pharmacopoeia (EP) Reference Standard;DTXSID60200600;Aspartame Impurity A;(3S,6S)-3-Benzyl-6-carboxymethyl-2,5-dioxopiperazin;(2S-cis)-(-)-5-Benzyl-3,6-dioxo-2-piperazineacetic acid, 97%;AKOS015916681;EINECS 226-075-1;2-(5-Benzyl-3,6-dioxopiperazin-2-yl)acetic Acid (Diketopiperazine)